Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Mar. Drugs 2006, 4(3), 193-214; doi:10.3390/md403193
Review

ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential

 and *
Received: 16 February 2006; Accepted: 28 February 2006 / Published: 6 April 2006
(This article belongs to the Special Issue Marine Drugs and Ion Channels)
View Full-Text   |   Download PDF [419 KB, uploaded 28 August 2008]
Abstract: Highly selective N-type voltage-gated calcium (CaV) channel inhibitors from cone snail venom (the ω-conotoxins) have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Earlier in 2005, Prialt (Elan) or synthetic ω-conotoxin MVIIA, was the first ω-conotoxin to be approved by Food and Drug Administration for human use. This review compares the action of three ω-conotoxins, GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved N-type therapeutics that are more useful in the treatment of chronic pain.
Keywords: ω-conotoxin; Structure-Activity relationship; pain ω-conotoxin; Structure-Activity relationship; pain
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Schroeder, C.I.; Lewis, R.J. ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential. Mar. Drugs 2006, 4, 193-214.

AMA Style

Schroeder CI, Lewis RJ. ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential. Marine Drugs. 2006; 4(3):193-214.

Chicago/Turabian Style

Schroeder, Christina I.; Lewis, Richard J. 2006. "ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential." Mar. Drugs 4, no. 3: 193-214.



Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert